Oral Loading of Phenobarbital to Achieve Therapeutic Effects in Pediatric Patients with Acute Repetitive Seizures

Q4 Medicine Annals of Child Neurology Pub Date : 2022-11-22 DOI:10.26815/acn.2022.00213
Jemima Grace D Fronda, Mel Michel G Villaluz, Cristina M. Cruz-Urbi
{"title":"Oral Loading of Phenobarbital to Achieve Therapeutic Effects in Pediatric Patients with Acute Repetitive Seizures","authors":"Jemima Grace D Fronda, Mel Michel G Villaluz, Cristina M. Cruz-Urbi","doi":"10.26815/acn.2022.00213","DOIUrl":null,"url":null,"abstract":"Purpose: Intravenous phenobarbital has not been available at our institution since 2019. This study aimed to determine the effectiveness of oral phenobarbital loading at a dose of 15 to 20 mg/kg to achieve therapeutic serum levels and clinical seizure control in pediatric patients with acute repetitive seizures. Methods: This is a retrospective single-center review of the medical records of pediatric patients admitted for acute repetitive seizures (from January 2019 to June 2022) at the Philippine Children’s Medical Center who were given an oral phenobarbital loading dose of 15 to 20 mg/kg with serum level measurements taken within 48 hours after oral loading. Results: Eleven patients were given a single oral phenobarbital loading dose of 15 to 20 mg/kg, while 14 were given two doses of 10 mg/kg 12 hours apart. All 25 patients achieved therapeutic serum levels within 48 hours post-loading. Higher serum levels were seen at 48 hours (median, 19.8 μg/mL at 24 hours vs. 24.4 μg/mL at 48 hours). This difference was statistically significant at 5% ( P =0.023), and the majority achieved adequate seizure control without requiring additional anti-seizure medications (76%). Transient drowsiness was the most commonly documented adverse effect. Conclusion: Oral loading of phenobarbital at a dose of 15 to 20 mg/kg given as a single dose or in two divided doses is an effective and safe alternative to achieve therapeutic serum levels and adequate clinical seizure control at 24 hours post-loading. This may be a promising and useful intervention at centers without available intravenous phenobarbital.","PeriodicalId":33305,"journal":{"name":"Annals of Child Neurology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Child Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26815/acn.2022.00213","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Purpose: Intravenous phenobarbital has not been available at our institution since 2019. This study aimed to determine the effectiveness of oral phenobarbital loading at a dose of 15 to 20 mg/kg to achieve therapeutic serum levels and clinical seizure control in pediatric patients with acute repetitive seizures. Methods: This is a retrospective single-center review of the medical records of pediatric patients admitted for acute repetitive seizures (from January 2019 to June 2022) at the Philippine Children’s Medical Center who were given an oral phenobarbital loading dose of 15 to 20 mg/kg with serum level measurements taken within 48 hours after oral loading. Results: Eleven patients were given a single oral phenobarbital loading dose of 15 to 20 mg/kg, while 14 were given two doses of 10 mg/kg 12 hours apart. All 25 patients achieved therapeutic serum levels within 48 hours post-loading. Higher serum levels were seen at 48 hours (median, 19.8 μg/mL at 24 hours vs. 24.4 μg/mL at 48 hours). This difference was statistically significant at 5% ( P =0.023), and the majority achieved adequate seizure control without requiring additional anti-seizure medications (76%). Transient drowsiness was the most commonly documented adverse effect. Conclusion: Oral loading of phenobarbital at a dose of 15 to 20 mg/kg given as a single dose or in two divided doses is an effective and safe alternative to achieve therapeutic serum levels and adequate clinical seizure control at 24 hours post-loading. This may be a promising and useful intervention at centers without available intravenous phenobarbital.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
口服苯巴比妥治疗小儿急性重复性癫痫疗效观察
目的:自2019年以来,我们机构没有提供静脉注射苯巴比妥。本研究旨在确定15至20 mg/kg剂量的口服苯巴比妥负荷对急性重复性癫痫儿童患者达到治疗血清水平和临床癫痫控制的有效性。方法:这是对菲律宾儿童医疗中心因急性重复性癫痫(2019年1月至2022年6月)入院的儿科患者的医疗记录的回顾性单中心审查,这些患者口服苯巴比妥负荷剂量为15至20 mg/kg,并在口服负荷后48小时内测量血清水平。结果:11名患者接受了15至20mg/kg的单次口服苯巴比妥负荷剂量,14名患者间隔12小时接受了10mg/kg的两次口服。所有25名患者均在负荷后48小时内达到治疗性血清水平。48小时血清水平升高(中位数为24小时19.8μg/mL,48小时24.4μg/mL)。这一差异具有统计学意义,为5%(P=0.023),大多数患者在不需要额外抗癫痫药物的情况下实现了充分的癫痫控制(76%)。短暂嗜睡是最常见的不良反应。结论:苯巴比妥单次或分两次口服负荷15至20mg/kg是一种有效且安全的替代方案,可在负荷后24小时达到治疗血清水平和充分的临床癫痫控制。在没有可用静脉注射苯巴比妥的中心,这可能是一种有前景和有用的干预措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annals of Child Neurology
Annals of Child Neurology Medicine-Pediatrics, Perinatology and Child Health
CiteScore
0.50
自引率
0.00%
发文量
35
审稿时长
8 weeks
期刊最新文献
Pediatric Headache: A Comprehensive Review A Novel Compound Heterozygous Mutation in the GALC gene in a Tunisian Family Impact of the COVID-19 Pandemic on Behavioral and Emotional Factors in Pediatric Patients with Headache Clinical Impact of Coronavirus Disease 2019 Outbreaks in Korea on Seizures in Children Clinical Analysis and Red Flag Signs in Pediatric Headache According to Age
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1